SCHEMBL4015525

SCHEMBL4015525

CC1CN(C(=O)O)CCc2ccc(N3CCC(F)CC3)nc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTR2C P28335 5/20 0.32
PDE10A Q9Y233 2/20 0.32
P2RX7 Q99572 3/20 0.32
MLNR O43193 1/20 0.32
HTT P42858 1/20 0.32
SCD O00767 1/20 0.32
HTR2A P28223 4/20 0.31
HTR2B P41595 4/20 0.31
HRH4 Q9H3N8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
FGFR1 P11362 1/20 0.31
PTGER4 P35408 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010642 1.00 LMNA (0.36) LMNAKDM4EALDH1A1MAPTHPGD
SCHEMBL4206510 1.00 LMNA (0.36) LMNAKDM4EALDH1A1MAPTHPGD
SCHEMBL4390364 0.88 PARP1 (0.36) ALDH1A1MAPTHPGD
SCHEMBL8059842 0.85 GPR119 (0.46) PDE10A
SCHEMBL8059846 0.85 GPR119 (0.46) PDE10A
SCHEMBL4206674 0.85 GPR119 (0.46) PDE10A
SCHEMBL2913101 0.78 KDM4E (0.41) LMNAKDM4EALDH1A1MAPTHPGD
SCHEMBL2910573 0.78 KDM4E (0.41) LMNAKDM4EALDH1A1MAPTHPGD
SCHEMBL2910571 0.78 KDM4E (0.41) LMNAKDM4EALDH1A1MAPTHPGD
SCHEMBL4203467 0.74 PIK3CD (0.44) LMNAKDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2009-12-17 US disclosed
EP-2094695-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS Cascade Therapeutics Inc. (CA) 2009-09-02 EP disclosed
WO-2009079765-A1 COMPOUNDS WITH ACTIVITY AT THE 5-HT2C RECEPTOR CASCADE THERAPEUTICS INC. (CA) 2009-07-02 WO disclosed
WO-2008009125-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS CASCADE THERAPEUTICS INC. (CA) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312306-A1 TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS HTR2C, HTR2A, HTR5A LMNA 3569/4885KDM4E 2942/4885ALDH1A1 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.